FY2026 EPS Estimates for ZVRA Lowered by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of Zevra Therapeutics in a research note issued to investors on Thursday, November 6th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of $0.43 per share for the year, down from their previous estimate of $0.55. Cantor Fitzgerald has a “Overweight” rating and a $24.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.

A number of other equities research analysts have also issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday. Zacks Research cut shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. JMP Securities cut their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Tuesday, October 14th. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.80.

Zevra Therapeutics Stock Down 3.1%

NASDAQ ZVRA opened at $8.81 on Friday. The business has a fifty day moving average price of $9.56 and a 200 day moving average price of $9.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The company has a market cap of $494.55 million, a P/E ratio of -41.95 and a beta of 1.52. Zevra Therapeutics has a one year low of $6.19 and a one year high of $13.16.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode purchased 5,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, August 19th. The shares were purchased at an average price of $9.16 per share, with a total value of $45,800.00. Following the transaction, the director owned 45,000 shares in the company, valued at $412,200. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the transaction, the chief executive officer owned 222,016 shares of the company’s stock, valued at $2,402,213.12. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently modified their holdings of ZVRA. CWM LLC increased its position in shares of Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares during the last quarter. Creative Planning purchased a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at approximately $92,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $99,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.